NEW: No-Cost StreetSmart Live! Events. This type of intellectual capital is usually not made available to the general public. Learn More

Sector Expert: Ross Silver

Sylva International , Vista Partners

Image: Ross Silver

Ross Silver has been advising, researching and investing in public companies across all industries throughout his career with a significant emphasis on biotechnology, technology and natural resources. Prior to founding Vista Partners LLC in 2005, Silver served as a research analyst for a San Francisco-based hedge fund. From 2000 to 2003, Silver served as a research associate covering consumer discretionary and consumer staple companies at Dresdner RCM (now Allianz). Prior to joining Dresdner RCM, Silver was a member of CIBC's Technology, Media, and Telecom Investment Banking group, where he assisted with equity and debt offerings. Silver holds a bachelor's degree in business economics from the University of California, Santa Barbara. He has served as a consultant for government agencies including the National Institutes of Health (NIH). He holds a Series 65 Securities license.

Recent Interviews

Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross Silver (5/20/15)

Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, the upside can be phenomenal. Enter Ross Silver of Vista Partners, who publishes research and owns many of the stocks he writes about. In this interview with The Life Sciences Report, Silver puts two biotech names on the table for investors to consider.

Ross Silver on How to Find the Perfect Combo of Biotech Science and Market Savvy (12/6/12)

Many components go into building a successful biotech company, but excellent management is a keystone. Combine good management with an innovative product or service, and investors can possibly unlock big multiples over their original investments. So says Principal Analyst and Fund Manager Ross Silver, co-founder of Vista Partners. In this interview with The Life Sciences Report, Silver brings obscure micro-cap ideas to life and discusses why they may have mammoth potential.

Recent Quotes

"SNGX's current valuation doesn't currently reflect the potential upside."

— Ross Silver, Vista Partners (4/19/16)
more >

"SNGX boasts a diverse pipeline with eight prospective drug candidates."

— Ross Silver, Vista Partners (12/18/15)
more >

"SNGX is an exciting company; it is rare to find a micro cap with such a diverse and broad clinical pipeline."

The Life Sciences Report Interview with Ross Silver (5/20/15)
more >

"INO has had a number of successes clinically and marquee collaborations that have led to its market cap being what it is today."

The Life Sciences Report Interview with Ross Silver (5/20/15)
more >

"The science behind SNGX's therapies continues to be validated by significant, important and influential entities."

— Ross Silver, Vista Partners (2/12/15)
more >

"CYD has potential to delineate significant resources at El Barqueño over the next 12 months."

— Ross Silver, Vista Partners (4/24/14)
more >

"We initiate coverage on URZ; its offtake agreements are for prices 50% higher than the current price of uranium."

— Ross Silver, Vista Partners (3/26/14)
more >

"We are initiating coverage on SNGX; we estimate its NPV to be $138M."

— Ross Silver, Vista Partners (3/18/14)
more >

Due to permission requirements, not all quotes are shown.